Is it time for one-step nucleic acid amplification (OSNA) in colorectal cancer? A systematic review and meta-analysis
- 85 Downloads
Lymph node metastasis (LNM) is prognostic in colorectal cancer (CRC). However, evaluation by routine haematoxylin and eosin histology (HE) limits nodal examination and is subjective. Missed LNMs from tissue allocation bias (TAB) might under-stage disease, leading to under-treatment. One-step nucleic acid amplification (OSNA) for CK19 messenger ribonucleic acid (mRNA), a marker of LNM, analyses the whole node. The aim of the present systematic review and meta-analysis was to assess recent studies on OSNA versus HE and its implications for CRC staging and treatment.
Databases including OVID, Medline and Google Scholar were searched for OSNA, LNM and CRC. Study results were pooled using a random-effects model. Summary receiver operator curves (SROC) assessed OSNA’s performance in detecting LNM when compared to routine HE histology.
Five case–control studies analysing 4080 nodes from 622 patients were included. The summary estimates of pooled results for OSNA were sensitivity 0.90 [95% confidence interval (CI) 0.86–0.93], specificity 0.94 (95% CI 0.93–0.95) and diagnostic odds ratio 179.5 (CI 58.35–552.2, p < 0.0001). The SROC curve indicated a maximum joint sensitivity and specificity of 0.88 and area under the curve of 0.94, p < 0.0001. On average, 5.4% HE-negative nodes were upstaged by OSNA.
OSNA is as good as routine HE. It may avoid TAB and offer a more objective and standardised assay of LNM. However, for upstaging, its usefulness as an adjunct to HE or superiority to HE requires further assessment of the benefits, if any, of adjuvant therapy in patients upstaged by OSNA.
KeywordsColorectal cancer Lymph node metastasis Prognosis One-step nucleic acid amplification OSNA
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All studies included in this analysis had ethical approval from their appropriate ethical bodies.
Formal consent was not required for this study.
- 1.Cancer IAfRo (2012) World Cancer Fact Sheet. GLOBOCON. 2013 ed. France: International Agency for Research on Cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed Feb 2017
- 2.UK OfNS (2014) Cancer survival in England: adults diagnosed 2008–2012, followed up to 2013 Office for National Statistics Website: ONS. http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Cancer-tab-data-tables. Accessed Feb 2017
- 11.Pathologists RCo (2014) Standards and datasets for reporting cancers dataset for colorectal cancer histopathology reports: Royal College of Pathologists. (updated July 2014; cited 2014 3rd Edition). http://www.rcpath.org/resourceLibrary/dataset-for-colorectal-cancer-histopathology-reports–3rd-edition-.html. Accessed Feb 2017
- 24.Aldecoa I, Atares B, Tarragona J et al (2016) Molecularly determined total tumour load in lymph nodes of stage I–II colon cancer patients correlates with high-risk factors. A multicentre prospective study. Virchows Arch 469(4):385–394. doi: 10.1007/s00428-016-1990-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.NICE (2017) Medtech innovation briefing 77. 24th August 2016. http://nice.org.uk/guidance/mib77. Accessed Feb 2017
- 36.Huxley N, Jones-Hughes T, Coelho H, Snowsill T, Cooper C, Meng Y et al (2015) A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technol Assess 19(2):5–25. doi: 10.3310/hta19020 CrossRefGoogle Scholar